UNSPSC 51391704: Alifedrine

This classification denotes a beta-adrenergic agonist with the molecular formula C18H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K2PM66M0VQ, chemically known as 1-propanone, 1-cyclohexyl-3-((2-hydroxy-1-methyl-2-phenylethyl)amino)-, (r-(r*,s*))- but generally known as alifedrine, which bears US NIH Compound Identifier 51719. Alifedrine comes in base and hydrochloride forms. European Medicines Agency schedules Alifedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05325MIG.

UNSPSC 51391704 Alifedrine (Commodity) describes pharmaceutical products used in emergency and community health settings, though recent state and local solicitations under this code show divergence from the nominal product scope. Seminole County, Florida and the Texas Health and Human Services Commission have posted opportunities acquiring naloxone and drug deactivation systems, as well as exploring direct-to-manufacturer prescription programs — acquisitions that fall outside the specific chemical agent named in the code itself. The work being solicited centers on procurement of emergency pharmaceuticals, opioid-reversal medications, and pharmacy benefit management services to support public health and employee health plans. Issuing bodies include county public health departments and state health agencies. The code shows limited recent activity, with only two opportunities visible in the recent record.

Seminole County, Florida accounts for the identified geographic concentration. The county issued IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; response deadline was July 26, 2023 (note: the posted date and due date appear inconsistent in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs and therapeutic pharmacy initiatives, with no formal response deadline or financial commitment. Neither opportunity specifies explicit set-asides for disadvantaged enterprises. The Seminole County procurement includes workers' compensation, commercial general liability, and professional liability insurance requirements, E-Verify compliance, and a three-month probationary period with termination at will.